VICTORIA, Oct. 9, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has signed an agreement and initiated an antibody development program with an undisclosed, top 15, global pharmaceutical company, to discover novel antibodies usingImmunoPrecise's proprietary hybridoma technology.
ImmunoPrecise's hybridoma platform allows for the selection of rare and slow-growing, IgG positive, monoclonal hybridomas in a semi-solid media format. Coupled with proprietary and abbreviated immunization regimes, the ability to sort cells and characterize and optimize lead candidates, ImmunoPrecise's platform allows for streamlined processes, condensed timelines, and the early identification of developability issues, mitigating the risk of significant losses in time and money.
Under this multi-year development agreement, this global pharmaceutical company receives contract research services using ImmunoPrecise's methods of discovering and developing antibodies in OmniAb® transgenic animals (Ligand Pharmaceuticals, NASDAQ:LGND), and intellectual property rights to develop and commercialize any resulting therapeutics.
The Agreement stipulates certain confidential provisions, including, at this stage, the pharmaceutical company's identity, target and the monetary size of contract.
ImmunoPrecise is currently in negotiations with several top 10 global pharmaceutical companies investigating the use of ImmunoPrecise's three full-service platforms, its advanced hybridoma platform, its proprietary and high demand B-cell selectplatform, and its phage display library platform. All three can be optimally leveraged for antibody discovery using various transgenic and wild-type animal strains.
"ImmunoPrecise can uniquely leverage three powerful platforms for antibody discovery to offer comprehensive campaigns that have the potential to deliver the antibody sequence diversity required to rapidly select the best lead candidates for further advancement" said Jennifer Bath, CEO and President of ImmunoPrecise Antibodies. "We've seen very strong interest in our diverse line of development platforms from a number of leading global pharmaceutical and biotech companies. "
|
|
